Hainan Huluwa Pharmaceutical Group Co Ltd

SHG:605199 China Drug Manufacturers - Specialty & Generic
Market Cap
$371.90 Million
CN¥2.73 Billion CNY
Market Cap Rank
#16857 Global
#4438 in China
Share Price
CN¥6.82
Change (1 day)
-1.45%
52-Week Range
CN¥6.64 - CN¥16.99
All Time High
CN¥48.21
About

Hainan Huluwa Pharmaceutical Group Co., Ltd. research, develops, produces, and sells drugs in the areas of Children's digestive system, respiratory system, anti-infection, anti-virus and other fields in China. The company offers pediatrics, gynecology, antibiotics, respiratory, digestive system, cardiovascular and cerebrovascular, nourishment, and other medicine products. Hainan Huluwa Pharmaceut… Read more

Hainan Huluwa Pharmaceutical Group Co Ltd (605199) - Cash Flow Conversion Efficiency

Latest cash flow conversion efficiency as of September 2025: 0.060x

Based on the latest financial reports, Hainan Huluwa Pharmaceutical Group Co Ltd (605199) has a cash flow conversion efficiency ratio of 0.060x as of September 2025.

Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥44.34 Million) by net assets (CN¥735.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Hainan Huluwa Pharmaceutical Group Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how Hainan Huluwa Pharmaceutical Group Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.

Hainan Huluwa Pharmaceutical Group Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hainan Huluwa Pharmaceutical Group Co Ltd ranked by their cash flow conversion efficiency.

Annual Cash Flow Conversion Efficiency for Hainan Huluwa Pharmaceutical Group Co Ltd (2016–2024)

The table below shows the annual cash flow conversion efficiency of Hainan Huluwa Pharmaceutical Group Co Ltd from 2016 to 2024.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥743.28 Million CN¥-149.12 Million -0.201x -923.26%
2023-12-31 CN¥1.16 Billion CN¥28.25 Million 0.024x -89.64%
2022-12-31 CN¥1.02 Billion CN¥238.71 Million 0.235x +113.48%
2021-12-31 CN¥930.52 Million CN¥102.48 Million 0.110x +2958.79%
2020-12-31 CN¥916.48 Million CN¥3.30 Million 0.004x -98.40%
2019-12-31 CN¥643.94 Million CN¥144.51 Million 0.224x +326.73%
2018-12-31 CN¥604.61 Million CN¥31.80 Million 0.053x -79.46%
2017-12-31 CN¥351.38 Million CN¥89.96 Million 0.256x -49.28%
2016-12-31 CN¥128.69 Million CN¥64.96 Million 0.505x --